News
Vir Biotech begins patient dosing in phase 1 trial of EGFR-targeting PRO-XTEN dual-masked T-cell engager VIR-5525 to treat solid tumours: San Francisco Saturday, July 26, 2025, 12 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback